|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||168.76 - 169.94|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.05|
|Dividend & Yield||4.60 (2.70%)|
|1y Target Est||N/A|
Amgen Inc.'s cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, according to a new study published in the medical journal JAMA Cardiology. ...
Regeneron Pharmaceuticals has launched three new drugs that could kick-start sales growth over the coming years.
Biotech has underperformed the broader market this month, but Jefferies' Michael Yee writes that that's not really a concern--or a surprise. A little more detail about each: AMGN: key incoming questions around scenarios for upcoming REGN injunction appeals decision where buyside consensus is for majority likelihood AMGN wins with some pot'l for court trying to force a financial settlement w/ large royalty (worth $2-3/share). If AMGN loses, there shouldn't be any change to estimates given consensus has not adjusted any 2018+ PCSK9 numbers for a win though AMGN already won the initial federal injunction decision.